IBT publicerar årsredovisning för 2018
April 04, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2018. Årsredovisningen finns tillgänglig på IBTs hemsida ibtherapeutics.com under avsnittet ”Investerare...
IBT publishes annual report for 2018
April 04, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2018. The report is available on IBT’s website ibtherapeutics.com under the section “Investors &...
Infant Bacterial Therapeutics AB sluter sitt första distributionsavtal
March 05, 2019 11:10 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB har idag gjort sitt första distributionsavtal för sin produkt IBP-9414 med Megapharm Ltd. avseende den israeliska marknaden och den palestinska myndighetens...
Infant Bacterial Therapeutics AB announces first distribution agreement
March 05, 2019 11:10 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB has today signed the first distribution agreement for IBP-9414 with Megapharm Ltd. for the Israeli market and the Palestinian Authority’s territories. The agreement...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 december 2018
February 08, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar IBT uppnådde flera viktiga milstolpar under 2018. Dels kontrakterades en CRO (Contract Research Organization) för att utföra den pivotala fas III-studien “The Connection Study”, och...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2018
February 08, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT reached several significant milestones during 2018. IBT reached agreement with a CRO (Contract Research Organization) to conduct the pivotal Phase III clinical trial, The...